Last reviewed · How we verify

Anesthesia maintenance , propofol,remifentanil,cisatracurium

Second Affiliated Hospital of Xi'an Jiaotong University · FDA-approved active Small molecule

Anesthesia maintenance , propofol,remifentanil,cisatracurium is a General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) Small molecule drug developed by Second Affiliated Hospital of Xi'an Jiaotong University. It is currently FDA-approved for Anesthesia maintenance during general surgery, Anesthesia induction and maintenance in intubated patients requiring mechanical ventilation.

This anesthetic regimen combines a GABA-A agonist (propofol), an opioid mu-receptor agonist (remifentanil), and a neuromuscular blocking agent (cisatracurium) to induce unconsciousness, analgesia, and muscle paralysis for surgical procedures.

This anesthetic regimen combines a GABA-A agonist (propofol), an opioid mu-receptor agonist (remifentanil), and a neuromuscular blocking agent (cisatracurium) to induce unconsciousness, analgesia, and muscle paralysis for surgical procedures. Used for Anesthesia maintenance during general surgery, Anesthesia induction and maintenance in intubated patients requiring mechanical ventilation.

At a glance

Generic nameAnesthesia maintenance , propofol,remifentanil,cisatracurium
SponsorSecond Affiliated Hospital of Xi'an Jiaotong University
Drug classGeneral anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker)
TargetGABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABA-A signaling in the central nervous system to produce sedation and hypnosis. Remifentanil activates mu-opioid receptors to provide analgesia and potentiate sedation. Cisatracurium is a non-depolarizing neuromuscular blocker that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle paralysis necessary for intubation and mechanical ventilation during surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anesthesia maintenance , propofol,remifentanil,cisatracurium

What is Anesthesia maintenance , propofol,remifentanil,cisatracurium?

Anesthesia maintenance , propofol,remifentanil,cisatracurium is a General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) drug developed by Second Affiliated Hospital of Xi'an Jiaotong University, indicated for Anesthesia maintenance during general surgery, Anesthesia induction and maintenance in intubated patients requiring mechanical ventilation.

How does Anesthesia maintenance , propofol,remifentanil,cisatracurium work?

This anesthetic regimen combines a GABA-A agonist (propofol), an opioid mu-receptor agonist (remifentanil), and a neuromuscular blocking agent (cisatracurium) to induce unconsciousness, analgesia, and muscle paralysis for surgical procedures.

What is Anesthesia maintenance , propofol,remifentanil,cisatracurium used for?

Anesthesia maintenance , propofol,remifentanil,cisatracurium is indicated for Anesthesia maintenance during general surgery, Anesthesia induction and maintenance in intubated patients requiring mechanical ventilation.

Who makes Anesthesia maintenance , propofol,remifentanil,cisatracurium?

Anesthesia maintenance , propofol,remifentanil,cisatracurium is developed and marketed by Second Affiliated Hospital of Xi'an Jiaotong University (see full Second Affiliated Hospital of Xi'an Jiaotong University pipeline at /company/second-affiliated-hospital-of-xi-an-jiaotong-university).

What drug class is Anesthesia maintenance , propofol,remifentanil,cisatracurium in?

Anesthesia maintenance , propofol,remifentanil,cisatracurium belongs to the General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) class. See all General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) drugs at /class/general-anesthetic-combination-gaba-a-agonist-opioid-neuromuscular-blocker.

What development phase is Anesthesia maintenance , propofol,remifentanil,cisatracurium in?

Anesthesia maintenance , propofol,remifentanil,cisatracurium is FDA-approved (marketed).

What are the side effects of Anesthesia maintenance , propofol,remifentanil,cisatracurium?

Common side effects of Anesthesia maintenance , propofol,remifentanil,cisatracurium include Hypotension, Bradycardia, Respiratory depression, Injection site pain (propofol), Postoperative nausea and vomiting, Muscle rigidity (remifentanil).

What does Anesthesia maintenance , propofol,remifentanil,cisatracurium target?

Anesthesia maintenance , propofol,remifentanil,cisatracurium targets GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium) and is a General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker).

Related